Skip to Content

COVID19: A message from the HLHS Consortium

We remain committed to conducting the vital work of bringing hope to CHD families through the development of regenerative medicine products. However, we respect that the situation is rapidly changing, and will only continue our work when and where it is safe to do so. We will continue to evaluate each cell delivery treatment on a case-by-case, site-by-site, and day-by-day basis.

Click here to read full message.

"We are going to transform congenital heart disease with new products. We are not going to do it by old products, we are not going to do it by old surgeries. We are not going to do it by yesterday's playbook."

-Dr. tim nelson, director of the hlhs consortium

The Todd and Karen Wanek Family Program for HLHS at Mayo Clinic created the HLHS Consortium to improve access to clinical trials and allow researchers to pool scientific knowledge with top cardiovascular programs around the country. The consortium helps decrease the amount of time from research and discovery to the clinical application of innovative cell-based therapies.

The most important goal of the HLHS Consortium is to ensure the highest level of care for your heart warrior and keep your family close to home.